Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis ...Middle East

YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented...

Hence then, the article about remegen announces exciting results of telitacicept phase 3 clinical trial for patients with generalized myasthenia gravis was published today ( Wednesday 09/04/2025 - 05:15 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis )

Also on site :

• Russia-Ukraine war: List of key events, day 1,428
• Thrash Metal Icon Reveals Truth About Final Album of 43-Year-Old Band
• Christina Haack Stuns in Bikini With Boyfriend on Tropical Getaway